Atjaunināt sīkdatņu piekrišanu

E-grāmata: Continuous Manufacturing for the Modernization of Pharmaceutical Production: Proceedings of a Workshop

  • Formāts: 68 pages
  • Izdošanas datums: 05-Mar-2019
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309487849
Citas grāmatas par šo tēmu:
  • Formāts - EPUB+DRM
  • Cena: 68,87 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 68 pages
  • Izdošanas datums: 05-Mar-2019
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309487849
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop.

Table of Contents



Front Matter Proceedings of a Workshop Appendix A: Workshop Agenda Appendix B: Biographies of Planning Committee Members, Speakers, and National Academies of Sciences, Engineering, and Medicine Staff Appendix C: Running Themes Across Workshop Sessions
Introduction
1(6)
Public-Private Partnerships to Help Realize the Promise of Continuous Manufacturing
1(3)
The Future of Access to Medical Countermeasures
4(2)
FDA's Interest in Continuous Manufacturing
6(1)
Business Case For Continuous Manufacturing
7(4)
Transforming Biopharmaceutical Production Through the Deployment of Next-Generation Biomanufacturing
7(2)
Continuous Manufacturing for Large Molecule Drugs
9(1)
Continuous Processing Beyond Financials
10(1)
Upstream Processing
11(5)
Fitting a Continuous Process into Existing Facilities
11(2)
Intensification of a Multi-Product Perfusion Platform
13(1)
Drivers, Challenges, and Implementation Solutions for Continuous Perfusion Manufacturing
14(2)
Downstream Processing
16(3)
Practical Considerations for Adoption
16(1)
What Can Be Learned from the Chemical Industry
17(1)
Turning Concept into Reality
18(1)
Product Manufacturing
19(6)
Drying Technologies to Stabilize Labile Molecules
19(2)
Solutions to Continuous Biomanufacturing Challenges
21(2)
Opportunities for Low-Cost Vaccine Manufacturing
23(2)
Integration
25(4)
A Case Study: Biologically Derived Medicines on Demand
25(1)
Strategy for Implementing Real-Time Release Testing
26(2)
Advancements Toward Real-Time Release
28(1)
Regulatory And Quality Aspects Of Continuous Manufacturing
29(7)
Key Aspects of Regulation
29(2)
Considerations for Virus Clearance Validation
31(3)
Considerations for Integrated Biomanufacturing
34(2)
Reports From Six Breakout Sessions
36(9)
Breakout Group 1 The Business Case
36(1)
Breakout Group 2 Upstream Processing
37(1)
Breakout Group 3 Downstream Processing
38(1)
Breakout Group 4 Product Manufacturing
39(1)
Breakout Group 5 Integration
40(1)
Breakout Group 6: Regulatory and Quality Aspects of Continuous Manufacturing
41(2)
References
43(2)
Appendixes
A Workshop Agenda
45(3)
B Biographies Of Planning Committee Members, Speakers, And National Academies Of Sciences, Engineering, And Medicine Staff
48(10)
C Running Themes Across Workshop Sessions
58